IN8bio, Inc. (INAB) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.22
↓-99% vs avg
5yr avg: 41.44
30Y Low0.4·High64.8
ROE
↓
-92.5%
↓+11% vs avg
5yr avg: -103.7%
30Y Low-239%·High-45%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
INAB Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
IN8bio, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $6M | $10M | $413M | $1.2B | $1.5B | $2.5B | — | — | — |
| Enterprise Value | $-17913287 | $-14074072 | $407M | $1.2B | $1.4B | $2.4B | — | — | — |
| P/E Ratio → | -0.31 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.22 | 0.37 | 28.55 | 49.58 | 63.92 | 64.78 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
INAB EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
INAB Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -92.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -92.5% | -92.5% | -154.4% | -125.9% | -93.6% | -51.9% | -95.2% | -238.7% | -44.8% |
| ROA | -73.0% | -73.0% | -111.4% | -89.9% | -75.8% | -46.4% | -77.6% | -146.2% | -35.3% |
| ROIC | -256.0% | -256.0% | -269.6% | -239.9% | -305.7% | -539.6% | — | — | — |
| ROCE | -84.5% | -84.5% | -131.8% | -109.3% | -84.9% | -50.3% | -90.9% | -172.3% | -36.6% |
INAB Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $27M exceeds total debt of $3M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | 0.35 | 0.20 | 0.26 | 0.06 | 0.01 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.88 | -0.42 | -0.66 | -0.54 | -0.91 | -0.97 | — | -1.07 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | -147.64 |
Net cash position: cash ($27M) exceeds total debt ($3M)
INAB Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
IN8bio, Inc.'s current ratio of 8.82x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 4.57x to 8.82x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.82 | 8.82 | 4.08 | 4.57 | 3.82 | 17.28 | 7.05 | 1.18 | 12.11 |
| Quick Ratio | 8.82 | 8.82 | 4.08 | 4.57 | 3.82 | 17.28 | 7.05 | 1.18 | 12.07 |
| Cash Ratio | 8.57 | 8.57 | 3.61 | 3.95 | 3.12 | 16.41 | 7.00 | 0.94 | 11.91 |
| Asset Turnover | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | 6.40 |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
INAB Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
IN8bio, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $4M | $54M | $30M | $21M | $19M | $19M | $19M | $19M |
Peer Comparison
Compare INAB with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 INABYou | $6M | -0.3 | — | — | — | — | -92.5% | -256.0% | — |
 FATE | $221M | -1.7 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 ADCT | $127M | -0.9 | — | — | 90.6% | -133.2% | — | — | — |
 IMVT | $7B | -12.1 | — | — | — | — | -64.8% | — | — |
 AGEN | $124M | -876.5 | — | — | 29.6% | -18.0% | — | — | — |
 CRSP | $5B | -8.0 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 EDIT | $231M | -1.3 | — | — | 100.0% | -245.2% | -198.1% | — | — |
 NTLA | $2B | -3.8 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 BEAM | $3B | -38.3 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 ALLO | $463M | -2.2 | — | — | — | — | -53.4% | -41.2% | — |
 CABA | $457M | -1.7 | — | — | — | — | -127.0% | -429.6% | — |
| Healthcare Median | — | 22.5 | 14.3 | 19.0 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
What if you invested $1,000 in INAB 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in INAB be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs INAB Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationINAB vs FATE — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Fate Therapeutics, Inc..
Compare NowINAB — Frequently Asked Questions
Quick answers to the most common questions about buying INAB stock.
What is IN8bio, Inc.'s P/E ratio?
IN8bio, Inc.'s current P/E ratio is -0.3x. This places it at the 50th percentile of its historical range.
What is IN8bio, Inc.'s ROE?
IN8bio, Inc.'s return on equity (ROE) is -92.5%. The historical average is -112.1%.
Is INAB stock overvalued?
Based on historical data, IN8bio, Inc. is trading at a P/E of -0.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.